Nie L, Chen X Q, Song Y K, Zhang M N, Xu M, Gong J, Zhou Q, Chen N
Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhonghua Bing Li Xue Za Zhi. 2022 Jul 8;51(7):634-639. doi: 10.3760/cma.j.cn112151-20210928-00718.
To investigate the clinical and pathological features and prognosis of patients with microfocal prostate adenocarcinoma. Clinical and pathological data of the patients diagnosed with microfocal adenocarcinoma on prostate biopsy at the West China Hospital from 2013 to 2019 were collected. Microfocal adenocarcinoma was defined as follows: Gleason score of 3+3=6, total number of the cores ≥10, number of the positive cores ≤2, and proportion of the tumor in each positive core<50%. Clinicopathological parameters, treatment plans and follow-up data were collected. Pathological information of the biopsy and radical resection specimens was used to analyze the correlation between pathological parameters in the biopsy report and adverse pathological features of radical resection specimens, including increased Gleason score, capsule invasion, positive surgical margin and perineural invasion. A total of 206 cases of microfocal adenocarcinoma were diagnosed on prostate biopsies from 2013 to 2019, accounting for 6.7% of all adenocarcinoma cases. There were 139 cases of 1 positive core and 67 cases of 2 positive cores. Patients with microfocal adenocarcinoma were younger than those with non-microfocal adenocarcinoma (69 years versus 71 years, <0.001). Compared with patients with non-microfocal adenocarcinoma, the pre-biopsy total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) levels in patients with microfocal adenocarcinoma were both lower (11.2 μg/L versus 23.7 μg/L; 1.4 μg/L versus 3.0 μg/L, <0.001), the fPSA/tPSA level was higher (12.9% versus 10.7%, <0.05), the prostate volume was larger (38.9 mL versus 34.3 mL, <0.05), and the PSA density was lower (0.3 μg/L versus 0.8 μg/L, <0.001). 130 patients underwent radical prostatectomy, 30 patients chose active monitoring, 31 patients chose endocrine or radiation therapy, and 15 patients were lost to follow-up. Three patients in the active surveillance group underwent radical prostatectomy for disease progression after 21-39 months observation. Biochemical relapses occurred in two patients in the radical prostatectomy group. The remaining patients have no disease progression or recurrence at present. Compared with radical prostatectomy specimens, Gleason score in the biopsy material was increased in 64/115 patients (55.7%). Among resection excision specimens, 14 cases (12.2%) had extraprostatic extension (EPE), 35 cases (30.4%) had perineural invasion, and 16 cases (13.9%) had a positive margin. Univariate and multivariate analyses showed that low fPSA/tPSA ratio and 2 positive cores were independent risk factors for Gleason score increase in the radical prostatectomy specimens. A low fPSA/tPSA ratio was an independent risk factor for perineural invasion. Low fPSA/tPSA ratio and low prostate volume were associated with a positive margin in radical prostatectomy specimens. In this study, patients diagnosed with microfocal adenocarcinoma on prostate biopsy account for a high proportion of the patients with increased Gleason score in the radical prostatectomy specimens, and there is a certain proportion of adverse pathological features in the radical specimens. Therefore, for the patients with only a small amount of low-grade adenocarcinoma found in biopsy, PSA levels and PSA density should be taken into consideration in treatment selection.
探讨微灶性前列腺腺癌患者的临床病理特征及预后。收集2013年至2019年在华西医院经前列腺穿刺活检诊断为微灶性腺癌患者的临床和病理资料。微灶性腺癌定义如下:Gleason评分3+3=6,穿刺针数≥10针,阳性针数≤2针,且每个阳性针中肿瘤比例<50%。收集临床病理参数、治疗方案及随访资料。利用穿刺活检及根治性切除标本的病理信息分析穿刺活检报告中的病理参数与根治性切除标本不良病理特征(包括Gleason评分增加、包膜侵犯、手术切缘阳性及神经周围侵犯)之间的相关性。2013年至2019年前列腺穿刺活检共诊断出206例微灶性腺癌,占所有腺癌病例的6.7%。其中1个阳性针的有139例,2个阳性针的有67例。微灶性腺癌患者比非微灶性腺癌患者年轻(69岁对71岁,<0.001)。与非微灶性腺癌患者相比,微灶性腺癌患者穿刺活检前总前列腺特异性抗原(tPSA)和游离前列腺特异性抗原(fPSA)水平均较低(11.2μg/L对23.7μg/L;1.4μg/L对3.0μg/L,<0.001),fPSA/tPSA比值较高(12.9%对10.7%,<0.05),前列腺体积较大(38.9mL对34.3mL,<0.05),PSA密度较低(0.3μg/L对0.8μg/L,<0.001)。130例患者接受了根治性前列腺切除术,30例患者选择主动监测,31例患者选择内分泌或放疗,15例患者失访。主动监测组有3例患者在观察21 - 39个月后因疾病进展接受了根治性前列腺切除术。根治性前列腺切除术组有2例患者发生生化复发。其余患者目前无疾病进展或复发。与根治性前列腺切除标本相比,115例患者中64例(55.7%)穿刺活检材料中的Gleason评分增加。在根治性切除标本中,14例(12.2%)有前列腺外侵犯(EPE),35例(30.4%)有神经周围侵犯,16例(13.9%)手术切缘阳性。单因素和多因素分析显示,低fPSA/tPSA比值和2个阳性针是根治性前列腺切除标本中Gleason评分增加的独立危险因素。低fPSA/tPSA比值是神经周围侵犯的独立危险因素。低fPSA/tPSA比值和低前列腺体积与根治性前列腺切除标本切缘阳性有关。本研究中,前列腺穿刺活检诊断为微灶性腺癌的患者在根治性前列腺切除标本中Gleason评分增加的比例较高,根治标本中存在一定比例的不良病理特征。因此,对于穿刺活检仅发现少量低级别腺癌的患者,治疗选择时应考虑PSA水平及PSA密度。